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Abstract
Background—Cardiac hypertrophy is a common response to circulatory or neurohumoral 
stressors as a mechanism to augment contractility. When the heart is under sustained stress, the 
hypertrophic response can evolve into decompensated heart failure, although the mechanism(s) 
underlying this transition remain largely unknown. Because phosphorylation of cardiac myosin 
light chain 2 (MLC2v), bound to myosin at the head-rod junction, facilitates actin-myosin 
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interactions and enhances contractility, we hypothesized that phosphorylation of MLC2v plays a 
role in adaptation of the heart to stress. We previously identified an enzyme that predominantly 
phosphorylates MLC2v in cardiomyocytes, cardiac-MLCK (cMLCK); yet the role(s) played by 
cMLCK in regulating cardiac function in health and disease remain to be determined.
Methods and Results—We found that pressure-overload induced by transaortic constriction in 
wildtype mice reduced phosphorylated-MLC2v levels by ~40% and cMLCK levels by ~85%. To 
examine how a reduction in cMLCK and the corresponding reduction in pMLC2v affect function, 
we generated Mylk3 gene-targeted mice as well as transgenic mice overexpressing cMLCK 
specifically in cardiomyocytes. Pressure-overload led to severe heart failure in cMLCK knockout 
mice, but not in mice with cMLCK overexpression in which cMLCK protein synthesis exceeded 
degradation. The reduction in cMLCK protein during pressure-overload was attenuated by 
inhibition of ubiquitin-proteasome protein degradation systems.
Conclusions—Our results suggest the novel idea that accelerated cMLCK-protein turnover by 
the ubiquitin-proteasome system underlie the transition from compensated hypertrophy to 
decompensated heart failure due to reduced phosphorylation of MLC2v.
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Introduction
In 2006, the overall death rate from cardiovascular disease was 262.5 per 100,000, of which 
1 in 8.6 deaths was due to heart failure. During failure, the heart is unable to pump sufficient 
blood to meet circulatory demand due to reduced myocardial force development 1. Pressure 
development and ejection are achieved by shortening of the minor- and long-axes of the 
heart, as well as twisting of the apex (torsion) due to differential orientation of ventricular 
myofibers in roughly three layers: inner-, mid- and outer 2–5. The dynamics of cardiac 
contraction and relaxation are fundamentally related to actin-myosin interactions which are 
initiated by Ca2+ binding to troponin C and relief of inhibition of crossbridge binding to 
actin. A range of factors regulate this process and contribute to the adaptation of cardiac 
function to physiological or pathological stressors 6–8, in turn suggesting potential 
therapeutic strategies for heart failure 9–11.
Myosin is a hexamer comprised of two heavy chains and two pairs of light chains (MLC1 
and MLC2) bound to the rod and neck regions of the heavy chain, respectively. 
Phosphorylation of MLC2v has been shown to potentiate the rate and force of cardiac 
contraction 12–16. Using mutant MLC2v knock-in mice in which two phosphorylatable 
serine residues were mutated to alanine (Ser14/15Ala), our recent study with others 
demonstrated that phosphorylation increases myosin binding and myosin lever arm stiffness, 
and alters the kinetics of crossbridge cycling to increase crossbridge duty ratio (stroke time/
cycle time). Furthermore, in addition to the traditional view of Ca2+-dependent activation of 
thin filaments, phosphorylated MLC2v can facilitate this process by activating neighboring 
binding sites on actin 17. Thus, nonphosphorylatable MLC2v in mice reduced contractility, 
and reduced phosphorylation of MLC2v has been implicated in human heart disease where 
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phosphorylation was reduced to ~18% of total MLC2v in failing hearts from ~30–40% in 
healthy hearts 18, 19.
The predominant kinase for MLC2v, cardiac-specific MLCK (cMLCK) encoded by Mylk3 , 
has been identified as a target of transcription factor Nkx2-5 20, and independently as a gene 
product that is differentially expressed in failing human hearts 21. Knockdown of cMLCK in 
neonatal cardiomyocytes and in zebrafish embryos resulted in abnormal formation of the 
sarcomere and depressed contraction 20, 21. A recent study using mice expressing 
hypomorphic cMLCK confirmed that cMLCK is the predominant MLC2v kinase in the 
heart and is important for normal cardiac contraction in vivo 22.
Under physiological conditions, the level of MLC2v phosphorylation is relatively constant 
due to countervailing actions of cMLCK and protein phosphatase 1β (PP1β, also termed 
PP1δ) in association with the myosin-binding phosphatase-target subunit (MYPT)23, 24. The 
level of MLC2v phosphorylation has been shown to vary through the thickness of the 
murine ventricular wall, being relatively low in the inner layer and high in the outer layer 13. 
This gradient has been proposed to be critical for non-uniform contractile properties of the 
myocytes across the wall, in particular for left ventricular (LV) torsion, the 
counterclockwise twisting of the LV apex, and clockwise twisting of the base during systole, 
when viewed from the apex 3–5. It has been thought that the gradient is formed by reduction 
of phosphatase activity in the outer layer 24, 25. However, the existence of a MLC2v 
phosphorylation gradient is still controversial 13, 22, and if it is present, the participation of 
MLC2v kinase as a determinant of the gradient remains to be clarified.
Based on these observations, we sought to investigate the role of cMLCK in the heart by 
determining its transmural expression and its functional roles through the use of loss- or 
gain-of-function mutations in mice.
Methods
Mouse models
A conditional null allele of Mylk3 was generated by introducing loxP sites spanning exon 5, 
which was done through homologous recombination in ES cells. Mice heterozygous for this 
Mylk3 allele were bred to mice expressing the ACTB1-Cre transgene, resulting in a germline 
Mylk3+/− allele, followed by cross-breeding to generate Mylk3−/− mice having a mixed 
genetic background mainly with 129/Sv and C57BL/6. Transgenic mice were generated by 
injection of HA-tagged full-length cMLCK cloned into an α-MHC promoter plasmid (kindly 
provided by J. Robbins)26. All animal experiments were performed with approval from the 
University of Florida Institutional Animal Care and Use Committee.
Human heart samples
Human heart samples were obtained from the National Human Tissue Resource Center. All 
protocols were approved by the University of Florida Institutional Review Board.
Additional experimental procedures are described in the supplement.
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Regional expression of cMLCK protein and phosphorylation of MLC2v in mouse and 
human hearts
We recently identified an enzyme that predominantly phosphorylates MLC2v in 
cardiomyocytes, cardiac-MLCK (cMLCK) 20. First, we confirmed that the regional 
expression of cMLCK and the extent of MLC2v phosphorylation (pMLCv) are almost 
identical in normal mouse hearts, although labeling of each exhibits non-uniform intensity 
across transverse tissue sections (Figures 1A, S1A). The staining of both was below the 
level of detection in the absence of cMLCK in Mylk3−/− mice (described later). Specificity 
of the pMLC2v antibody against phosphorylated MLC2v was confirmed by Western 
blotting (Figure S2).
At higher magnification, cMLCK staining was more diffuse in the cytoplasm compared to 
the striated staining pattern of pMLC2v (Figure 1B). Globally, expression of cMLCK and 
pMLC2v were higher in the right ventricle (RV) than in the LV (Figures 1C, D). In the LV, 
higher levels of expression were observed in the mid to outer epicardial layers than in the 
inner endocardial layer at interventricular septal wall (Figures 1C–H). A few layers of 
myofibers at the surface of the endocardium highly expressed cMLCK and pMLC2v 
(Figures 1I–L). These cells are Purkinje fibers, which form a ventricular conduction system 
marked by the presence of the gap junction protein connexin40 (Figure 1M). In human 
hearts, levels of cMLCK and pMLC2v were also high in Purkinje fibers which were co-
stained for atrial natriuretic factor (ANF)(Figure 1N). Notably, the antibody against 
connexin40 was not compatible with the paraffin-sections of the human heart.
These data confirm that cMLCK is the predominant kinase for MLC2v, which is highly 
expressed in the mid- and epicardial layers compared to the endocardial layer of the LV 
consistent with a previous report 13, and has even greater expression in the RV and Purkinje 
fibers.
Reductions in cMLCK and pMLC2v after pressure-overload
The transmural expression of cMLCK proteins and pMLC2v was quantified by Western 
blotting of tissue from hearts subjected to pressure-overload by transverse aortic constriction 
(TAC) for 3 months. The endocardial layers significantly thicken following TAC, making 
them easier to dissect (Figure 2A). cMLCK expression and MLC2v phosphorylation were 
higher in the RV than the LV and were below the level of detection in the endocardial layers 
(Figures 2B, C, S2B). Our previous study showed that ~30% of total MLC2v was 
phosphorylated in normal mouse hearts 20. In the remaining experiments described (unless 
otherwise specified), cMLCK and pMLC2v expression were examined in the apical third of 
the heart to minimize variations due to regional expression of cMLCK. Reductions in 
cMLCK and pMLC2 were evident as early as 1 week after TAC, by ~85% and ~40%, 
respectively, compared to control mice (Figures 2D, E).
One week of TAC resulted in ventricular wall thickening without apparent changes in 
cardiac function (%FS) or chamber diameters (Figures 2F, G, 1 week). Two weeks of TAC 
significantly reduced %FS and increased systolic dimensions compared to control values or 
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1 week of TAC in our experimental conditions (Figures 2F, G). Thus, the functional 
transition from compensated to decompensated cardiac hypertrophy occurred between 1 and 
2 weeks of TAC, shortly after reductions in cMLCK and pMLCv.
Deletion of Mylk3 leads to moderate abnormalities in contraction and conduction under 
basal conditions
Data from mice with TAC suggest that reduced cMLCK expression and MLC2v 
phosphorylation may be involved in both chronic and transitional (from compensated to 
decompensated) cardiac hypertrophy. To examine this possibility mechanistically, we first 
generated Mylk3 gene-targeted mice and examined whether the absence of cMLCK affects 
cardiac function. Germline-deletion of floxed-exon 5 resulted in elimination of the first 
coding exon of the catalytic domain and a frame-shift of the subsequent downstream exons 
(Figure 3A, Figure S3). cMLCK mRNA expression was below the level of detection in 
Mylk3−/− hearts by Northern blotting using a cDNA probe that recognizes exons 1 to 6 
(1266 bp)(Figure 3B). This result is likely attributable to a nonsense-mediated mRNA 
decay 27, with targeted cMLCK mRNA containing a premature termination codon. In 
Mylk3−/− hearts, MLC2v phosphorylation was below the level of detection (Figure 3C), 
consistent with immunostaining in Figure 1A.
Mylk3−/− mice were born at the expected Mendelian ratios and survived through adulthood 
beyond 1.5 years of age. Mylk3−/− hearts were moderately enlarged predominantly along the 
long-axis with increased heart weight at 3 and 6 months of age (Figures 3D, E). Neither 
cytoarchitectural disarray nor increased interstitial fibrosis was observed (Figure 3F). 
Cardiac contraction assessed using MRI (Figure 3G, supplemental movies) and 
echocardiography (Figure S4) demonstrated a reduction in ejection fraction and increases in 
the volume of the left ventricular cavity both at end-systole and end-diastole. Cardiac torsion 
was also reduced in Mylk3−/− hearts compared to control mice (Figure 3G).
Isolated ventricular cardiomyocytes from adult Mylk3−/− mice were larger than 
cardiomyocytes from control mice, and displayed reductions in contractility and speed of 
relaxation with no changes in amplitude of the intracellular Ca2+ transient (Figures 3H, I).
In the ventricular conduction system, cMLCK and pMLC2v were present at higher levels 
than in the rest of the LV (Figures 1K–N). Ambulatory telemetry ECG recordings 
demonstrated a small but significant prolongation of the QRS complex in Mylk3−/− mice 
compared to age- and sex-matched Mylk3+/+ controls (Figures S5A–C), indicating that 
ventricular depolarization was prolonged in Mylk3−/− mice. This could be due all or in part 
to elongation of the ventricular conduction system secondary to enlargement of the heart 
(Figure S5D).
Adaptation to pressure-overload requires cMLCK
In contrast to the finding that Mylk3−/− mice showed a moderate reduction in contractility 
under basal conditions, 3 months TAC resulted in profound heart failure in these mice, 
associated with increased heart size (Figure 4A), decreased survival rate (Figure 4B), and 
increased heart weight/tibial length (Figure 4C). Hereafter, heart weight is normalized to 
Warren et al. Page 5













tibial length in reporting results of TAC studies, since there is an increase in body weight by 
accumulation of body fluid due to profound heart failure after TAC, particularly in Mylk3−/− 
mice.
Mylk3−/− mice had markedly increased LV dimensions at end-diastole and systole with 
reduced contractility (Figures 4D–E). LV end-systolic pressure (~100 mmHg without TAC) 
was increased to ~180 mmHg after TAC in Mylk3+/+ mice, but not in Mylk3−/− mice (~120 
mmHg, Figures 4F–G). Instead, Mylk3−/− mice exhibited a marked increase in end-diastolic 
pressure, and reduced rates of contraction (+dP/dt) and relaxation (−dP/dt). These 
measurements revealed profound systolic and diastolic dysfunction in Mylk3−/− mice 
(Figures 4F, G).
One week of TAC did not affect cardiac contractility or chamber dimensions in Mylk3+/+ 
mice. In contrast, Mylk3−/− mice showed a progressive reduction in %FS and increased end-
systolic dimension (Figures 2F–G, 4H, S6). Although cardiac function and heart size 
differed in Mylk3−/− vs. Mylk3+/+ mice prior to TAC, Mylk3−/− mice displayed no 
compensatory response to TAC (Figure 4H: pre-TAC %FS was 25% reduced compared with 
Mylk3+/+ mice, and fell further 1 week after TAC to ~40%).
Role of cMLCK in response to 4 weeks of swimming exercise
Besides the hypertrophic response to pressure-overload, the heart can also exhibit 
hypertrophic growth as an adaptation to exercise. This adaptation results in an increase in 
absolute force production by the ventricular wall due at least in part to increase in the total 
number of actin-myosin motor units working in parallel 28. To understand the role of 
cMLCK in the response of the heart to exercise, 3 month-old Mylk3−/− and Mylk3+/+ mice 
were subjected to 4 weeks of swim training (Figure 5A).
Wildtype mice tolerated 4 weeks of swimming, while 25% of Mylk3−/− mice died during or 
shortly after exercise (Figure 5B). Both Mylk3+/+ and surviving Mylk3−/− mice 
demonstrated an increased heart weight/body weight (Figure 5C); however, exercise failed 
to improve cardiac contraction evident as a reduction in %FS in Mylk3−/− mice compared to 
control Mylk3+/+ (Figure 5D) and to sedentary Mylk3−/− mice at a similar age from 26% to 
19% (Figure S4, 3 months of age). In Mylk3+/+ but not in Mylk3−/− mice, swimming 
increased pMLC2v to 39% (33% without swimming) (Figure 5E), and increased expression 
of cMLCK protein (Figures 5E, F). These results indicate that cMLCK is the predominant 
kinase mediating increased MLC2v phosphorylation in response to swim training.
Increased expression of fetal genes, such as ANF and brain natriuretic peptide (BNP), is 
often observed in failing hearts but was not seen in sedentary Mylk3−/− mice (no 
swimming), consistent with moderate cardiac dysfunction without an increase in interstitial 
fibrosis (Figure 3F). Exercise-induced hypertrophy normally does not increase expression of 
ANF and BNP (Figure 5G, +/+ no swim vs. swim)29, 30. Despite the reduction in %FS in 
Mylk3−/− mice after exercise, there was no substantial increase in ANF or BNP before vs. 
after exercise in Mylk3−/− mice.
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Overexpression of cMLCK protects against pressure-overload induced cardiac 
dysfunction
Profound heart failure in pressure-overloaded Mylk3−/− mice supports our hypothesis that 
reduced cMLCK expression and MLC2v phosphorylation are involved in decompensated 
TAC-induced cardiac hypertrophy. We further examined whether excess cMLCK protects 
the heart during short-and long-term pressure-overloading using a second mouse model that 
over-expresses cMLCK under the control of α-myosin heavy chain (α-MHC) promoter/
enhancers. Among five transgenic lines, three lines expressed cMLCK relatively 
homogenously in the LV (data not shown) and were further examined. The level of 
transgenic protein expression relative to the endogenous cMLCK in non-TG (NTG) mice 
ranged from 6.5-fold in line TG1 to 21-fold in TG2 and TG3 (Figure 6A), leading to a 
moderate increase in pMLC2v from 34% of total MLC2v in NTG to 42–50% in the 
transgenics (Figure 6B). Basal cardiac function in the three transgenic lines was not 
statistically different from NTG, with the exception of a slight reduction in end-diastolic 
dimensions in TG3 (Figure S7A).
1 week TAC reduced transgenic proteins expression, similar to endogenous cMLCK 
proteins (Figure 6C), despite endogenous and transgenic cMLCK having different promoter/
enhancers, exon-intron structures, and 3’ poly-A tails. These results suggest that the 
reduction in cMLCK protein by pressure-overload is regulated by post-transcriptional 
mechanisms.
While NTG and TGs were subjected to similar degrees of pressure-overload (Figure 6D), 
the increase in heart weight (determined by heart weight/tibial length) was attenuated in 
transgenics, including the TG3 line with higher cMLCK expression (Figure 6D). 
Attenuation was accompanied by a parallel reduction in cardiomyocyte cell size and 
preservation of contractility at 2 and 4 weeks after TAC (Figures S7B, S7C). After chronic 
pressure-overload (3 months; degree similar in all groups; Figure S8A), and reductions in 
both endogenous and transgenic cMLCK proteins (Figure S8B), cardiac function was 
significantly preserved in the high-expressor TG3 line vs. NTG with respect to contractility 
and chamber size (Figures 6E, F), interstitial fibrosis (Figure 6G), and apoptosis (Figures 
6H, S9).
These results further support our hypothesis that elevated expression of cMLCK protein (6.5 
to 21-fold higher than endogenous) protects the heart against cardiac dysfunction during 
short- and long-term pressure-overload.
Involvement of the ubiquitin-proteasome system in cMLCK protein degradation
To understand potential mechanisms underlying the reduction in cMLCK protein during 
pressure-overload, we explored the possible role of the ubiquitin-proteasome system, the 
major non-lysosomal pathway for intracellular protein degradation. Recently, altered activity 
of the ubiquitin-proteasome system has been emphasized in studies of cardiac 
hypertrophy 31–33. Target proteins are polyubiquitinated by concerted action of three 
enzymes: E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme) and E3 
(ubiquitin-ligase) prior to degradation by the 26S proteasome composed of the 20S catalytic 
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and 19S regulatory cores 31–33. Both synthetic and natural proteasome inhibitors block 
proteasome activity: synthetic peptide aldehyde, such as MG132, mimics proteasome 
substrates, binds to the proteasome active site, and transiently disrupts its activity. A natural 
inhibitor, lactacystin, covalently binds to the β-subunit of 20S unit and irreversibly and more 
specifically block its activity 34.
We first examined whether endogenous cMLCK expression was upregulated by two 
different proteasome inhibitors, MG132 (Figure S10) and lactacystin (Figure 7A). Both 
inhibitors increased cMLCK expression in cardiomyocytes. Next, mice were treated with 
lactacystin, MG132, or both MG132 and lactacystin 3 hrs prior to the TAC operation, 
followed by daily injection of the inhibitors for 1 week. In comparison to the 80% reduction 
in cMLCK protein after 1 week of TAC without proteasome inhibitors (Figure 7B, lane 1 vs. 
2), addition of proteasome inhibitors attenuated the reduction of cMLCK proteins by 
40-60% in all 3 groups and was most effective when the two inhibitors were used in 
combination (Figure 7B). In contrast to reduced cMLCK expression after TAC, the 
expression of MLC2v and myosin binding protein C (MyBP-C) assessed on the same 
membrane was unchanged with or without TAC (Figure 7C). Proteasome inhibitors 
increased the expression of MyBP-C but not MLC2v. Thus, TAC-induced reductions and 
partial rescue by proteasome inhibitors were observed for cMLCK but not MLC2v or 
MyBP-C.
Third, in the fraction of ubiquitylated proteins enriched by TUBE (tandem ubiquitin binding 
entity)-conjugated beads from the same amount of heart lysate, cMLCK antibodies 
preferentially recognized proteins with several different molecular weights in the heart 
lysate from pressure-overloaded Mylk3+/+ hearts in the presence of proteasome inhibitors 
(Figure 7C).
Substrate specificity of ubiquitin-ligation is determined by E3 ligases. Among ~10 muscle-
specific E3 ligases, muscle-specific RING finger protein 1 (MuRF1) and atrogin1/MAFbx, 
are the most intensively studied muscle specific E3 ligases 32, and are upregulated in rodent 
hypertrophic models 35. Overexpression of E3 ligases, including MuRF1 and atrogin 1, has 
been shown to promote degradation of target proteins in cultured cardiomyocytes 36, 37 but 
not cMLCK by adenovirus infection into mouse neonatal cardiomyocytes from ~5 to 20 moi 
(Figures 7E, F).
Collectively, these results suggest that ubiquitin-proteasome-dependent protein degradation 
and/or processing participates in reduction of cMLCK protein due to TAC, which was not 
seen for two other proteins and was independent of MuRF1 or atrogin1 in cultured 
cardiomyocytes.
Discussion
Potential mechanism(s) underlying the transition from compensated to decompensated heart 
failure are largely unknown. In this study, we demonstrated that functional transition from 
compensated to decompensated hypertrophy occurred between 1 and 2 weeks of TAC. 
Reduced cMLCK expression and MLC2v phosphorylation occurred as early as 1 week and 
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continuously during TAC, suggesting a role for MLC2v phosphorylation in this transition 
and under chronic pressure-overload. Second, this possibility was examined mechanistically 
in loss- and gain-of function cMLCK mutant mouse models. TAC led to severe heart failure 
in Mylk3−/− mice but did not affect cardiac contractility in cMLCK-overexpressing mice 
when the level of cMLCK expression exceeded that of the normal heart. Third, this process 
involved ubiquitin-proteasome dependent protein degradation. Fourth, increased cMLCK 
expression and MLC2v phosphorylation were observed in exercise-induced cardiac 
hypertrophy after 4 weeks of swim training in Mylk3+/+ mice with unchanged contractility; 
while induction of MLC2v phosphorylation was not observed in Mylk3−/− mice, which 
exhibited 25% mortality and reduced contractility. Collectively, these data demonstrate that 
reduced cMLCK expression and consequent reduction of pMLC2 play a pivotal role in 
mediating the transition from compensated to decompensated hypertrophy. Also, induction 
of cMLCK is critical for the cardiac adaptive response to exercise stress, presumably due to 
MLC2v phosphorylation-dependent facilitation of crossbridge formation as discussed in our 
earlier study 17.
Transgenic mice overexpressing cMLCK did not display an obvious cardiac phenotype 
(based on size or function) under basal conditions even with an ~21-fold increase in 
expression. Following TAC, however, beneficial effects were evident, including 
maintenance of contractility without fibrosis or apoptotic cell death. Levels of exogenous, 
transgenically expressed cMLCK protein were also substantially decreased by TAC. Thus, a 
greater than 6.5-fold induction of cMLCK under basal conditions causes protein synthesis to 
exceed degradation during TAC, and the increased levels of cMLCK are sufficient to have a 
beneficial effect on cardiac function after TAC.
Proteasome inhibitors could attenuate, at least in part, the fall in cMLCK protein after TAC: 
however, inhibition of proteasomal processing does not necessarily improve cardiac function 
in rats 38. The proteasome inhibitor, Bortezomib, is the first FDA-approved for clinical 
application. Patients with multiple myeloma treated with Bortezomib demonstrated 
cardiotoxicity including heart failure, as did normal rats 39, 40. Thus, a more specific 
methodology to attenuate cMLCK protein degradation during overloading must be 
identified. Because substrate specificity is defined by E3 ligases, we reasoned that 
identification of an E3 ubiquitin-ligase specific for cMLCK might be a step in this direction. 
The two best characterized muscle-specific E3 ligases, MuRF1 and atrogin1, however, 
failed to reduce cMLCK expression in cardiomyocytes. Thus, identification of cMLCK-
specific E3 ligases as well as how proteasomal processing works on cMLCK, whether it be 
by degradation and elimination or a process yielding biological active polypeptide fragments 
of cMLCK, remain to be elucidated 41.
Exercise is a stressor of the heart resulting in regional adaptive hypertrophy and alterations 
in contractility and biochemical properties of myocardial proteins 42. Typically, greater 
responses to exercise are observed in endocardial than epicardial layers 42. In this study, 
swimming increased the expression of cMLCK and phosphorylation of MLC2v. Mylk3−/− 
mice exhibited cardiac dysfunction in response to chronic exercise and also reduced survival 
compared to control Mylk3+/+ mice. These findings are in contradistinction to the beneficial 
effects of exercise reported in other genetic mouse models with cardiac dysfunction, in 
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which exercise improved cardiac function and/or lifespan 43, 44. Collectively, this suggests 
cMLCK plays an essential role by inducing a beneficial adaptation of the heart to exercise, 
which is consistent with pMLC2v playing a critical role in cardiac adaptation to increased 
loading of the heart, such as occurs with regular exercise 45.
We also found that spatial distributions of pMLC2v and cMLCK expression were nearly 
identical, and were neither homogenous nor simple gradients between the inner and outer 
layers of the rodent heart 13. Non-uniform distributions of cMLCK and pMLC2v are 
consistent with previous observations that the ventricular walls are not homogenous in terms 
of size, electro-physiological coupling, or active wall stress under basal conditions 46–48. It 
is possible that expression of cMLCK is related to spatial orientation of fibers and 
corresponding variations in fiber stress, which may confer to myocytes across the wall 
variable contractile properties that contribute to LV torsion 3–5, 13. In this regard, torsion was 
substantially reduced in Mylk3−/− and MLC2v (Ser14/15Ala) knock-in mutant mice 17.
cMLCK expression is higher in RV than in LV myocardium, exhibiting an inverse 
relationship to systolic pressure (~17 mmHg in RV49 vs. ~100 mmHg in LV). cMLCK 
expression in the LV was markedly downregulated due to TAC. Furthermore, cMLCK is 
highly expressed in the specialized cardiomyocytes of the ventricular conduction system, 
even though the contractile protein content in these cells is substantially less than in 
contractile myocytes. These results could be interpreted as showing that increased 
mechanical stress reduces net expression of cMLCK by increasing ubiquitin-proteasome 
activity. It is also possible that cMLCK expression and pMLC2v levels are related to 
diastolic pressure, decreasing with chronic increases in diastolic pressure as proposed 
previously 50. Of course, both active and passive stresses vary within the wall as a function 
of the radius of curvature, which in turn varies with depth within the wall and also position 
along the base-apex axis. Viewed in this way, an inverse relationship between wall stress 
and cMLCK and pMLC2v expression might provide a regulatory mechanism by which 
variations in stress are normalized.
With respect to the ventricular conduction system, our observation of high levels of cMLCK 
expression and pMLC2v in normal mouse and human hearts was unexpected. It seems 
unlikely that increased cMLCK and pMLC2v would influence the activity of the conduction 
system, although our experiments do not rule out this possibility.
Our finding of depressed cardiac contraction in near complete absence of MLC2v 
phosphorylation in our Mylk3−/− mice is consistent with results of a recent study using 
hypomorphic cMLCK mutant mice 22. However, our Mylk3−/− mice demonstrated milder 
cardiac dysfunction without an increase in interstitial fibrosis, and only a marginal increase 
in fetal gene expression including ANF and BNP under basal conditions. The milder 
phenotype displayed in our Mylk3−/− mice might be attributed to the absence of NeoR 
cassettes, or differences in mouse genetic backgrounds and other experimental conditions 51.
A limitation of this study is that cardiac function was different between the mouse models 
(mutants vs. wildtype) under basal conditions prior to being subjected to a cardiac stress. 
This was particularly true for Mylk3−/− mice. However, since we observed reciprocal 
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phenotypes in mice with constitutively less or more cMLCK, our conclusions appear to be 
sound.
In summary, this study demonstrates that cMLCK plays essential roles in cardiac 
adaptations to exercise and pressure overload. Development of heart failure under pressure 
overload is attenuated by greater expression of cMLCK without apparent adverse effects on 
normal cardiac function in the absence of increased loading. Thus, an increase in expression 
of cMLCK or enhancement of its function is a potentially important therapeutic strategy for 
the treatment of heart failure resulting from pressure overload (i.e., hypertensive heart 
failure).
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cMLCK protein and phosphorylated MLC2v expression.(A) Immunostaining of cMLCK 
and pMLC2v (purple) in transverse sections of Mylk3+/+ and Mylk3−/− adult hearts 
counterstained with 10-fold diluted eosin (pink). Bar = 1 mm. (B) Enlarged images of 
immunostaining. Bars = 10 µm. (C–L) Distribution of cMLCK (top panels) and pMLC2v 
(bottom panels) in serial sections from LV and RV of Mylk3+/+ . Bars = 500 µm (C–F), 50 
µm (G–L). (M) Fluorescent immunostaining of serial tissue-sections of Mylk3+/+ heart 
including Purkinje fibers using antibodies against cMLCK, pMLC2v and connexin40 
(green, all rabbit polyclonal antibodies) with nuclear staining (blue). Bars = 50 µm. (N) 
Immunostaining of serial tissue-sections of human heart including Purkinje fibers locating in 
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the endocardial layer using antibodies against human cMLCK, pMLC2v, and ANF (all 
rabbit polyclonal antibodies). Bars = 100 µm.
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Reduction of cMLCK in mouse hearts due to pressure overload. (A) Immunostaining of 
cMLCK and pMLC2v (purple) in transverse serial sections of TAC heart counterstained 
with eosin (pink). (B) Western blotting of cMLCK, total MLC2v and GAPDH in RV, the 
entire LV and the endocardial layer (endo) dissected from a TAC heart. (C) 
Unphosphorylated and phosphorylated MLC2v in RV, LV and papillary muscles dissected 
from TAC hearts examined with 2D-electrophoresis followed by Western blotting with an 
anti-MLC antibody. (D) Western blotting of cMLCK, pMLC2v, total MLC2v and GAPDH 
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after 1 week of TAC (lanes 6–9) and control (lanes 1–5). (E) Fold difference of cMLCK, 
pMLC2v and total MLC2v normalized to GAPDH with the value without TAC defined as 1. 
(F) Representative images of sequential M-mode ultrasound of a Mylk3+/+ mouse from pre-
operation to 4 weeks of TAC. (G) Echocardiographic indices of Mylk3+/+ mice before and 
during TAC. Time-dependent effects were not significant in ED dimension and HR using 
repeated measure ANOVA. *P < 0.05.
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Moderate heart enlargement and reduced contractile function in Mylk3−/− mice. (A) PCR 
genotyping demonstrates ~1750 bp in Mylk3+/+ (lane 1) vs. ~800 bp in Mylk3−/− (lane 2). 
(B) Northern blotting shows that cMLCK mRNA (4.3 kb) is below detection levels in 
Mylk3−/− mice (lane 1 vs. 2). (C) Unphosphorylated and phosphorylated MLC2v examined 
with 2D-electrophoresis followed by Western blotting (left panel) and relative amounts of 
phosphorylated to total MLC2v (right panel). (D) Representative hearts dissected from 
Mylk3+/+ and Mylk3−/− mice at 3 months of age. Bars = 2 mm. (E) HW/BW (mg/g) at 3 and 
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6 months of age. (F) Representative heart sections with Masson’s trichrome staining and 
area size of fibrosis (% relative to the total area examined). Bars = 1 mm (top), 100 µm 
(middle and bottom panels). (G) Cardiac contraction, wall volume, wall thickness and 
torsion examined using MRI at 3 months of age. Calculation of cardiac torsion is shown. See 
Supplemental material (video). (H) Representative images of cardiomyocytes, cell area 
(µm2), long axis (µm) and short axis (µm) at 3 months of age. Bars = 100 µm. (I) 
Measurements of cardiac contraction and simultaneous Ca2+ transients in isolated 
cardiomyocytes. ED, end-diastolic; ES, end-systolic; %FS, % left ventricular fractional 
shortening. *P < 0.05.
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Heart failure in Mylk3−/− mice after pressure overload.(A) Representative images of hearts 
after 3 months of TAC. Bar = 2 mm. (B) Survival analysis during 3 months of TAC. Several 
mice died shortly after the operation (1 week) and were eliminated from these studies in 
consideration of post-operative complications. (C) HW/tibial length (mg/mm) after 3 
months of TAC. (D–E) Representative images of M-mode ultrasound and echocardiographic 
indices after 3 months of TAC. (F–G) Representative tracing of LV pressure, dP/dt and 
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summarized data from hemodynamic measurements after 3 months of TAC. (H) Sequential 
ehocardiographic indices from pre-operation to 4 weeks TAC. *P < 0.05.
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Effects of cMLCK on cardiac adaptations to physiological stress.(A) Representative images 
of hearts dissected after 4 weeks of swimming exercise. Bars = 2 mm. (B) Survival analysis 
during 4 weeks of swimming exercise. (C) HW/BW with or without 4 weeks of swimming 
exercise at ~4 months of age. (D) Echocardiographic indices after swimming exercise. (E) 
Unphosphorylated and phosphorylated MLC2v examined with 2D-electrophoresis followed 
by Western blotting and relative amounts of phosphorylated to total MLC2v. (F) Western 
blotting of cMLCK, pMLC2v, total MLC2v and GAPDH with or without swimming 
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exercise. Fold difference of cMLCK and pMLC2v normalized to total MLC2v with the 
value in Mylk3+/+ without swimming exercise defined as 1. (G) Real-time RT PCR 
demonstrates relative expression of ANF and BNP mRNA normalized to β-actin mRNA 
with the value in Mylk3+/+ without swimming exercise defined as 1. *P < 0.05.
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Overexpression of cMLCK attenuates pressure overload-induced pathological hypertrophic 
responses. (A) Schematic of the transgenic construct. Western blotting demonstrates 
transgenic protein expression in three lines of transgenics using antibodies against cMLCK 
(top panel) and HA (lower panel). Relative expression compared to the endogenous cMLCK 
proteins is shown. (B) Unphosphorylated and phosphorylated MLC2v examined with 2D-
electrophoresis followed by Western blotting and relative amounts of phosphorylated to total 
MLC2v (n=2-4 hearts from each line). (C) Western blotting of heart lysates with or without 
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1 week of TAC using antibodies against cMLCK, HA, pMLC2v, MLC2v and GAPDH. (D) 
Summarized data of LV systolic pressure and HW/tibial length with or without 1 week of 
TAC. Representative M-mode ultrasound images (E) and echocardiographic indices (F) 
following 3 months of TAC. (G) Masson’s trichrome staining of heart sections and area size 
of fibrosis (% relative to the total area size examined) following 3 months of TAC. Bar = 50 
µm. (H) Representative co-staining for TUNEL, DAPI and troponin T of LV following 3 
months of TAC, and summary for TUNEL positive nuclei (% of total nuclei). Bar= 20 µm. 
Total number of nuclei counted is indicated. MHC, myosin heavy chain; NTG, non-
transgenic; TG, transgenic. *P < 0.05.
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Involvement of the ubiquitin-proteasome system in cMLCK protein degradation. (A) 
Representative Western blotting of ubiquitin and cMLCK as well as Coomassie stained actin 
using cultured neonatal mouse cardiomyocytes with or without lactacystin treatments (5 and 
10 µM) for 24 or 48 hrs. (B) Representative Western blotting of cMLCK using heart lysate 
obtained from mice treated with the proteasome inhibitors, lactacystin and/or MG132 s(1 
mg/kg/day). GAPDH expression is also shown. Expression of cMLCK normalized to 
GAPDH is shown with the value for TAC(-) defined as 1. (C) Western blotting of MLC2v 
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and MyBP-C probed using the same membrane used as in Figure 7B. (D) Western blotting 
of cMLCK in heart lysates from the pressure-overload Mylk3+/+ hearts in the presence of 
proteasome inhibitors (lanes 1, 2) or Mylk3−/− (lane 3) enriched by TUBE-conjugated beads 
(left panel), and cMLCK and GAPDH in the input heart lysates (right panel). Representative 
Western blotting of cMLCK after infection of adenovirus encoding MuRF1 and atrogin1 at 
~5 moi and (E) upto 20 moi (F). Expression of cMLCK normalized to GAPDH is shown 
with the value for control (5 moi adenovirus-GFP) defined as 1 (E).
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